Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...

A late-stage study tested three doses of Eli Lilly’s oral GLP-1 drug, Orforglipron, in more than 3,100 adults, with the ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company also released long-awaited ...

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

Sales of Danish drugmaker Novo Nordisk 's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month ...

Influencer Tana Mongeau has warned against taking the weight loss drug Mounjaro after she experienced severe side effects.